title: Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: a comparison with fusidic acid.
abstract: The efficacy and safety of ciprofloxacin ophthalmic solution (0.3%) and fusidic acid gel (1%) were compared in the treatment of bacterial conjunctivitis and blepharitis in a randomized, open, parallel group study. Thirty-nine patients, 21 treated with ciprofloxacin solution and 18 treated with fusidic acid gel, were culture-positive on admission and were evaluable for efficacy. At the end of a 7-day treatment, the infecting organism was eradicated in 81% of those treated with ciprofloxacin and 72% of those treated with fusidic acid gel. There was clinical cure or improvement in 95% and 89% respectively. The clinical cure rate appeared to be higher with ciprofloxacin than fusidic acid (62% compared with 28%) but this was related to the higher proportion of patients with acute conjunctivitis in the ciprofloxacin group. Two patients using ciprofloxacin had mild discomfort and stinging on instillation and one given fusidic acid had moderate edema and discomfort; the latter patient stopped treatment. Topical ciprofloxacin is effective and well tolerated and is a useful treatment of bacterial conjunctivitis and blepharitis.
authors.affiliation: CHU Dupuytren, Limoges, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Adenis
authors.forename: J
authors.initials: J
authors.lastname: Colin
authors.forename: P
authors.initials: P
authors.lastname: Verin
authors.forename: I
authors.initials: I
authors.lastname: Riss
authors.forename: P
authors.initials: P
authors.lastname: Saint-Blancat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001762:Blepharitis / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D003228:Conjunctiva / Q000187:drug effects / Q000382:microbiology; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy* / Q000209:etiology; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000209:etiology; D005143:Eyelids / Q000187:drug effects / Q000382:microbiology; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005782:Gels; D006090:Gram-Negative Bacteria / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D012449:Safety
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D005782:Gels; D009883:Ophthalmic Solutions; D005672:Fusidic Acid; D002939:Ciprofloxacin